scroll

CSL Limited (CSL)

CSL $171.48

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

CSL $171.48

20 MINUTE DELAYED

TODAY

-2.38 %

1 YEAR RETURN

0.00%

VOLUME

542,529

DIV YIELD

2.64%

PE RATIO

18.12

52 WEEK RANGE

168.00

290.32

ANALYSIS
OPINION
ACTION

ANALYSIS

Overview

SHARE PRICE ACTIVITY
Last (Price)	171.48
Change	-4.18 (-2.38)
Bid / Ask	171.48 - 171.80
Volume	542,529
Turnover	93,736,961
Open	175.60
Day Range	171.48 - 175.82
VWAP	172.79
Prev Close	175.66
Last Trade	24/12 2:20pm (AEST)

KEY INFORMATION
Sector	Healthcare
Shares Issued	484,109,213
NTA/Share	0.00
Last Dividend	2.45
Dividend Ex Date	09 SEP 2025
Dividend Pay Date	03 OCT 2025

CURRENT ()
Revenue	14,800.00
EBITDA	4,894.00
Profit	2,907.00
Earnings Per Share (EPS)	0
Dividend Per Share (DPS)	0
Yield %	2.64
Market Cap	0
Price to Earnings Ratio (P/E)	18.12

TARGET PRICE FORECAST

ESTIMATES ()
Revenue	15,996.16
EBITDA	5,495.39
Profit	3,364.25
Earnings Per Share (EPS)	6.97
Dividend Per Share (DPS)	3.08

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation (BUY)

2.06

OPINION

28/10/2025 17:28

CSL Limited (CSL) 177.86

CSL -15.87: Belted today, down as much as 17% to the lowest level since 2018, after the company scrapped its 2026 target to demerge Seqirus. The reason? A sharp drop in US flu vaccination rates (-12% overall, -14% in seniors), pushing Seqirus revenues into a mid-teens decline and undermining the value case for a standalone listing.

16/09/2025 09:53

Active Growth Portfolio – Amendment

MM is amending the Growth Portfolio

16/09/2025 09:42

CSL Ltd (CSL) $204.48

After CSL’s aggressive sell-off last month, it's been the topic of conversation with many investors caught long this much-loved $99bn healthcare giant. We discussed CSL in detail following August's result, which led to the sell-off despite earnings being up 14%, cash flow growing 29%, and the company announcing a $750 million share buyback.

20/08/2025 09:30

CSL Ltd (CSL) $225.50

CSL dominated talk across trading desks on Tuesday with their messy, but not particularly bad, result causing the stock to be punished almost 17%, its worst fall since the GFC.

19/08/2025 17:53

CSL Limited (CSL) $225.50

CSL –16.89%: Shares experienced their worst fall since 2008 after the FY25 result highlighted weakness in the Behring division and revealed a major strategic restructure including a spinoff of Seqirus, which has created more questions than answers.

14/08/2025 09:33

CSL Ltd (CSL) $269.55

CSL advanced 2% yesterday in a weak market, leading the healthcare sector to a 1% gain. The $130bn global biotech has struggled since COVID but we believe its defensive nature and cheap valuation compared to history puts it in an excellent position to rerate on the upside.

08/07/2025 09:52

Active Growth Portfolio – Amendments

We are making two changes to the Active Growth Portfolio, trimming an existing holding and buying a new stock.

01/05/2025 09:23

CSL Ltd (CSL) $251.13

The market's third-largest company, blood plasma giant CSL, advanced +2.3% on Wednesday, with ~20% of the gain occurring in the “Match.” The stock has range-traded since 2020 as it’s struggled to maintain an attractive growth profile, almost inevitable with a market cap of ~$120bn.

27/02/2025 09:22

Revisiting healthcare stocks as investors become more defensive

We recently sold CSL and HLS out of the MM Active Growth Portfolio, leaving us with no healthcare exposure to this ~9% sector of the ASX200. Hence, we are carefully looking for attractive risk/reward opportunities in companies in the space we like.

21/02/2025 09:57

Active Growth Portfolio – Amendments

MM are making several changes to the Active Growth Portfolio today

ACTION

CSL

UPDATED 28/10/2025 17:37 ACTIVE

MM will remain patient on CSL for now

Add To Hit List

Read the opinion

CSL

UPDATED 28/10/2025 13:50 ACTIVE

MM is long and cautiously bullish towards CSL

Add To Hit List

CSL

UPDATED 16/09/2025 18:24 ACTIVE

MM is long and bullish CSL ~$200

Add To Hit List

Read the opinion

CSL

UPDATED 16/09/2025 18:23 ACTIVE

MM is adding to CSL in Active Growth Portfolio, targeting a 5% portfolio weighting

Add To Hit List

Read the opinion

CSL

UPDATED 20/08/2025 09:47

MM is cautiously long and bullish CSL around $225

Add To Hit List

Read the opinion

CSL

UPDATED 20/08/2025 08:26

MM is long but now cautious toward CSL

Add To Hit List

Read the opinion

CSL

UPDATED 14/08/2025 09:51

MM is long and bullish CSL

Add To Hit List

Read the opinion

CSL

UPDATED 10/07/2025 10:09

MM is bullish towards CSL around $250

Add To Hit List

Read the opinion

CSL

UPDATED 10/07/2025 10:07

MM are buying CSL in the Active Growth Portfolio, allocating 4% around $250

Add To Hit List

Read the opinion

CSL

UPDATED 01/05/2025 09:39

MM is neutral to cautiously bullish CSL ~$250

Add To Hit List

Read the opinion

Business Summary

CSL Limited (CSL) is a global biotechnology company that develops and delivers innovative medicines that save lives, protect public health and help people with life-threatening medical conditions live full lives. CSL is also involved in research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. CSL's operating model for its two businesses, CSL Behring and Seqirus.

WATCH

Pulse Check Webinar: Opportunities in the unloved parts of the market Recorded Wednesday 27st September

27/09/2023 15:28

Related Q&A

Relevant suggested news and content from the site

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required

For membership options and pricing. Click here

CSL Limited (CSL)

CSL $171.48

14 DAYS FREE ACCESS

CSL $171.48

BROKER CONSENSUS RECOMMENDATION

OPINION

CSL Limited (CSL) 177.86

Active Growth Portfolio – Amendment

CSL Ltd (CSL) $204.48

CSL Ltd (CSL) $225.50

CSL Limited (CSL) $225.50

CSL Ltd (CSL) $269.55

Active Growth Portfolio – Amendments

CSL Ltd (CSL) $251.13

Revisiting healthcare stocks as investors become more defensive

Active Growth Portfolio – Amendments

ACTION

Business Summary

Relevant suggested news and content from the site

You're trying to view member-only content

Get free access

Become a member

CSL Limited (CSL)

CSL $171.48

14 DAYS FREE ACCESS

CSL $171.48

PERFORMANCE

BROKER CALLS

BROKER CONSENSUS RECOMMENDATION

OPINION

ACTION

Business Summary

Video

Relevant suggested news and content from the site

Video

Podcast

Video

Podcast

Video

Podcast

Only available to Members

Really bullish, there's more to go in the reflation rally

Please enter your login details

To reset your password, enter your email address

Enter and confirm your new password

Congratulations your password has been reset

Sorry, but your key is expired.

Sorry, but your key is invalid.

Something go wrong.

Only available to Market Matters members

Smart Phone App

You're trying to view member-only content

Get free access

Existing member? login here.

Become a member